'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs

Current Opinion in Cardiology

Volumn 22, Issue 4, 2007, Pages 335-343

  Staessen, Jan A ^a,d   Thijs, Lutgarde ^a   Li, Yan ^b   Kuznetsova, Tatiana ^a   Richart, Tom ^a   Wang, Jiguang ^b   Birkenhäger, Willem H ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d Studies Coordinating Centre   (Belgium)

Author keywords

blocker; ACE inhibitor; Angiotensin receptor blocker; Blood pressure; Calcium channel blocker; Diuretic

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PERINDOPRIL; VALSARTAN;

ANALYTIC METHOD; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IATROGENIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; REVIEW; RISK; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIURETICS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 34250194022     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3281eb8e8d     Document Type: Review

References (59)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
2. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
3. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
6. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
7. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet 2004; 363:2022-2031.
8. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051.
9. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an amlodipine±perindopril strategy compared with an atenolol±thiazide strategy. The Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
10. Poulter NR, Wedel H, Dahlo±f B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm. Lancet 2005; 366:907-913.
11. Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. Hypertension 2003; 42:69-75.
12. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
13. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis [erratum published in The Lancet, 2002; 359:360]. Lancet 2001; 358:1305-1315.
14. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. J Hypertens 2003; 21:1055-1076.
15. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28:385-407.
16. Verdecchia P, Reboldi G, Angeli A, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46:386-392.
17. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
18. Casas JP, Chua W, Loukogoergakis S, et al. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033.
19. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25:951-958. This metaregression analysis confirmed small 'benefit beyond blood pressure lowering' of ACE inhibitors in the prevention of myocardial infarction.
20. Messerli FH, Staessen JA. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies [correction published in Hypertension 2006; 48:e24]. Hypertension 2006; 48:359-361.
21. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease change with aging? The Framingham Heart Study. Circulation 2001; 103:1245-1249.
22. Staessen JA, Birkenhäger WH. Evidence that new hypertensives are superior to older drugs. Lancet 2005; 366:869-871.
23. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthan-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOTT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
24. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
25. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
27. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
28. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
29. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364:849-857.
30. Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21:2409-2417.
31. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
32. Staessen JA, Wang JG, Birkenhäger WH. Outcome beyond blood pressure control? Eur Heart J 2003; 24:504-514.
33. Staessen JA, Thijs L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22:847-857.
34. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for the primary and secondary prevention of stroke. Hypertension 2006; 48:187-195. Comprehensive review of the reversibility of the risk of stroke in relation to blood pressure.
35. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327:669-677.
36. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
37. Staessen JA, Birkenháger WH. VALUE: to the heart of the matter. J Hypertens 2004; 22:1431-1434.
38. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [erratum published in The Lancet, 1997; 350:1636]. Lancet 1997; 350:757-764.
39. Staessen JA, Thijs L, Birkenhäger WH. VALUE: analysis of results. Lancet 2004; 364:931.
40. Emberson JR, Whincup PH, Morris RW, Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 2003; 24:1719-1726.
41. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J 2004; 328:1519-1527.
42. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639.
43. Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2007; 27:2982-2988. This analysis illustrated the potential of multiple risk factor intervention in hypertensive patients with at least three additional risk factors.
44. Gæde P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
45. Messerli FH, Bakris G, Ferrera RD, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens 2006; 8:571-581.
46. Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (The Amlodipine/ Atorvastatin Gemini Study). J Clin Hypertens 2006; 7:264-273.
47. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967-1975.
48. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207. This network meta-analysis reported on the relative differences in the incidence of iatrogenic diabetes mellitus on various classes of antihypertensive drugs in comparison with diuretics, but did not translate relative into absolute benefit.
49. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2005; 43:963-969.
50. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension. Lancet 2004; 364:1684-1689.
51. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
52. Higgins B, Williams B, Bakhshi L, et al. Management of hypertension in adults in primary care: partial update. London, United Kingdom: Royal College of Physicians 2006.
53. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
54. Staessen J, Bulpitt C, Cattaert A, et al. Secondary prevention with betaadrenoceptor blockers in postmyocardial infarction patients. Am Heart J 1982; 104:1395-1399.
55. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1622-1623.
56. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
57. Hansen TW, Staessen JA, Torp-Pedersen C, et al. Ambulatory arterial stiffness index predicts stroke in a general population. J Hypertens 2006; 24:2247-2253.
58. Kikuya M, Staessen JA, Ohkubo T, et al. Ambulatory arterial stiffness index and 24-h ambulatory pulse pressure as predictors of mortality in Ohasama, Japan. Stroke 2007 (in press).
59. Dickerson JEC, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major drug classes. Lancet 1999; 353:2008-2013.